Novel Biologics

OVERVIEW

New candidate therapeutic antibodies are being developed at our Utrecht site using Bioceros’ proprietary Custom Assays for Specific Hybridomas (CASHTM) technology followed by humanization. New Biologic Entities (NBEs) are a new area of focus for Polpharma Biologics, in which the detailed process knowledge acquired through the development of biosimilars can be combined with the extensive discovery experience of the Utrecht site to develop these innovative therapies. This alliance within the organization enables us to advance these novel medicines into clinical studies and provides partnership opportunities for their full clinical development. For interest in a potential partnership, please contact us.

 

Candidate Selection

Bioceros leverages the broad knowledge of its expression and immunology teams to design and develop customized screening assays to select their therapeutic candidates. The proprietary CASHTM technology is employed by an antibody discovery team with decades of experience and a robust track record validated by several out-licensed programs. The latter is exemplified by the successful out-licensing of one of Bioceros’ previous checkpoint modulator antibodies to J&J.


A Novel Approach to Pathogenic Neutrophils

The first program focuses on the prevention of pathogenic neutrophilic damage in tissues. Neutrophils are the most ignored cell type of the immune system and play a pathogenic role in many auto-immune diseases. This novel approach is unique in both its target and therapeutic potential for neutrophilic disease, in which treatment options are severely lacking. A significant proportion of auto-immune patients who are not responding to TNF inhibitors have high neutrophil involvement in the disease.

The candidate antibodies being developed by Polpharma Biologics can prevent the activation of neutrophils and inhibit the release of chemo-attractive signals and pathogenic molecules, making them unique in their class. Furthermore, for proper patient selection, a companion diagnostic can easily be developed.


Targeting the Immune Suppressive Tumor Macroenvironment

Our validated expertise in immunotherapy prompted the discovery and generation of innovative antibodies to new checkpoint inhibitor targets. Compared to the PD1-PD-L1 axis for these novel targets, the respective receptors are upregulated in various oncologic indications. Patients who are suffering from tumors with high expression of these novel checkpoint inhibitor targets have an immune suppressive tumor microenvironment and a poor prognosis. Since the ligand is expressed on immune cells, inhibition of these pathways will result in immune stimulation.


Novel Biologics Pipeline

Code / Molecule
Originator
Type
Therapeutic Area
PN1212
N / A
NBE
Not disclosed
Early Tech Dev
Late Tech Dev
PhI
PhIII
Submission
Approval
INTERESTED IN LEARNING MORE?

For partnership, investment or licensing opportunities, or to learn more about our programs currently in development, we invite you to reach out to us directly.

INTEGRATED CAPABILITIES

View our biopharmaceutical CDMO services or learn more about our own pipeline of biosimilars currently in development.

CDMO

Polpharma Biologics offers a full range of development and manufacturing services for both biosimilar and innovative programs. Our services are available on a standalone basis or as part of a long-term strategic alliance.

Learn More

Biosimilars

Leveraging our expertise in mammalian cell culture and microbial production, Polpharma Biologics develops biosimilars, with a pipeline of six products. We welcome inquiries around partnering and co-development.

Learn More